ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
SYDNEY, Australia, Aug. 15, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) is pleased to announce that it has received a €876,635 (A$1,306,266) cash rebate from the French Government under its Crédit d’Impôt Recherche scheme (CIR). Through CIR the French government reimburses companies, whether French or international, for undertaking research and development activity in France by up to 30%.
Prima BioMed qualifies to receive CIR credits via its subsidiary Immutep due to R&D conducted in its laboratory at Châtenay-Malabry in southwestern Paris in the 2016 calendar year. Prima is currently working on new products in addition to the development work related to lead compound IMP321, in both cancer treatment and other settings.
The additional funding will be used for the development of its IMP321 clinical trial programs in Europe and Australia.
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please contact: U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected] Australian Investors/Media: Matthew Gregorowski, Citadel-MAGNUS +61 2 8234 0105; [email protected]
